

JUL 28. 2005 11:23AM AVENTIS US PAT DEPT
TO: US CENTRALIZED USPTO

RECEIVED
CENTRAL FAX CENTER

JUL 28 2005

NO. 7151 P. 1/3

PTO/SB/21 (09-04)

Approved for use through 07/31/2005. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

3

Application Number

10/774,721

Filing Date

February 09, 2004

First Named Inventor

Ralf JOCKERS et al.

Art Unit

1635

Examiner Name

WOLLENBERGER, Louis V.

Attorney Docket Number


FRAV2003/0005 US NP

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	sanofi-aventis		
Signature			
Printed name	Karen I. Krupen		
Date	July 28, 2005	Reg. No.	34,647

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571 273-8300 ; Total No. of Pages Transmitted: 3)			
Signature			
Typed or printed name	Delia Coughlin	Date	7/28/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
JOCKERS et al.

Examiner: **Wollenberger, Louis**

Art Unit: **1635**

RECEIVED
CENTRAL FAX CENTER

Application No.: **10/774,721**

JUL 28 2005

Filed: **February 9, 2003**

Title: **OLIGONUCLEOTIDES WHICH INHIBIT
EXPRESSION OF THE OB-RGRP PROTEIN AND
METHOD FOR DETECTING COMPOUNDS
WHICH MODIFY THE INTERACTION
BETWEEN PROTEINS OF THE OB-RGRP
FAMILY AND THE LEPTIN RECEPTOR**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is
being transmitted via facsimile to the
Commissioner for Patents, Alexandria,
VA 22313, on

Date of transmission July 28, 2005

Signature Karen Krupen

RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sirs:

In response to the Office Action dated June 15, 2005 in connection with the above-identified application, Applicants elect to prosecute the claims of Group II (claims 12-17 and 42-44) and further elect the species SEQ ID NO: 37.

Respectfully submitted,

Karen Krupen

Karen I. Krupen, Reg. No. 34,647
Attorney for Applicants

sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626
Aventis Docket No. FRAV2003/0005 US NP